Scivision Biotech (TPE:1786) Total Debt per Share: NT$6.64 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1786 Scivision Biotech Inc TPE:1786
77 GF Score
Price NT$47.05
GF Value NT$101.67
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Scivision Biotech Total Debt per Share?

Scivision Biotech TPE:1786 +6.21% 77 Total Debt per Share is NT$6.64 as of Jun. 2026. GuruFocus rates TPE:1786 with a GF Score™ of 77/100 and a GF Value™ of NT$101.67 (Significantly Undervalued). The stock has 3 warning signs investors should review.

NT$6.64 (As of Jun. 2026)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Scivision Biotech's Total Debt Per Share for the quarter that ended in Jun. 2026 was NT$6.64.

Scivision Biotech Total Debt per Share Historical Data

* Premium members only.

The historical data trend for Scivision Biotech's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scivision Biotech Total Debt per Share Chart

Scivision Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Debt per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.60 6.29 5.14 3.12 6.48

Scivision Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.30 6.73 6.48 6.48 6.64
TPE:1786
77GF Score
Scivision Biotech Inc TPE:1786
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scivision Biotech Total Debt per Share Calculation

Scivision Biotech's Total Debt Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(474.4+10.7)/74.8
=6.48

Scivision Biotech's Total Debt Per Share for the quarter that ended in Jun. 2026 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(475.3+10.3)/73.2
=6.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of NT$6.64 mean?
Scivision Biotech (TPE:1786) has a Total Debt per Share of NT$6.64 as of Jun. 2026. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Scivision Biotech and its competitors.
Is Scivision Biotech's Total Debt per Share too high?
Scivision Biotech's current Total Debt per Share is NT$6.64. Overall, Scivision Biotech has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scivision Biotech's Total Debt per Share compare to ISRG and BDX?
Scivision Biotech's Total Debt per Share of NT$6.64 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Medical Devices & Instruments company?
A good Total Debt per Share depends on the Medical Devices & Instruments industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Scivision Biotech and its competitors. Scivision Biotech's current Total Debt per Share is NT$6.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scivision Biotech stock overvalued right now?
Based on GuruFocus' analysis, Scivision Biotech (TPE:1786) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$101.67, compared to a current price of NT$47.05 — trading 53.7% below its estimated fair value. The current Total Debt per Share is NT$6.64. Scivision Biotech's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For Scivision Biotech (TPE:1786), the current Total Debt per Share is NT$6.64 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Scivision Biotech (TPE:1786) Overvalued in 2026?

Based on GuruFocus' analysis, Scivision Biotech stock appears to be undervalued. The current stock price of NT$47.05 is trading 53.7% below its estimated GF Value™ of NT$101.67. GuruFocus considers Scivision Biotech to be Significantly Undervalued.

Key valuation signals for TPE:1786:

  • Total Debt per Share: NT$6.64
  • GF Value™: NT$101.67 vs. price of NT$47.05 (53.7% below fair value)
  • GF Score™: 77/100 with 3 warning signs

No single metric tells the full story. See the TPE:1786 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Scivision Biotech Business Description

Address No. 1, South 1st Road, Qianzhen District, Kaohsiung, TWN, 806
Scivision Biotech Inc is engaged in the manufacturing and distribution of hyaluronic acid medical supplies in Taiwan. It offers medical devices, including absorbable adhesion barriers, dermal implants, synovial fluid supplements, and intravesical instillation.
77GF Score

Get the complete analysis for TPE:1786

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$47.05
Price
NT$101.67
GF Value